Pharma China (www.pharmachinaonline.com) is the most influential English media and source of business intelligence covering the Chinese pharmaceutical sector. Pharma China caters for the growing needs of the international pharmaceutical industry for up-to-date and insightful information and intelligence on China’s burgeoning but increasingly complex healthcare marketplace, and is subscribed by most MNC pharma companies, leading CROs, investment banks, consulting firms active in China as well as relevant industry associations and government agencies.

Note: To view full text of free articles, you need to register as a basic member first and then log in. To view premium articles, you need to subscribe to Pharma China as a premium member. For more information or subscription, please contact info@pharmachinaonline.com. If you wish to unsubscribe from this e-Alert, please reply this e-mail with "Remove" in the subject line.
Industry News
Merck's MilliporeSigma Opens its Largest M Lab Collaboration Center in Shanghai(7/9/2020 )  (Premium)
Roche Launches Collaborative Program in China for Digestive Tract Immunotherapies(7/9/2020 )  (Premium)
Clover Biopharma Receives $66M from CEPI for COVID-19 Vaccine Candidate(7/9/2020 )  (free)
Turning Point and Zai Lab Announce Exclusive License Deal for Repotrectinib in Greater China(7/7/2020 )  (Premium)
SinoPharm Completes New Vaccine Plant in Wuhan, Doubling Capacity(7/7/2020 )  (free)
Regulatory News
CDE Launches Updated Drug Clinical Trial Registration and Information Publication System(7/10/2020 )  (Premium)
CDE Launches Online Application Systems for Breakthrough Medicines and Priority Review(7/10/2020 )  (Premium)
CDE Issues the Guidelines for Format/Style and Collation of Drug Administration Application Dossiers(7/9/2020 )  (Premium)
NMPA Issues the Working Procedure for Priority Review and Approval of Drug Marketing Authorizations (Interim)(7/8/2020 )  (Premium)
NMPA Issues Working Procedures for Drug Marketing Evaluation and Approval with Attached Conditions (Interim)(7/8/2020 )  (Premium)
NMPA Issues Working Procedures for Evaluation and Approval of Breakthrough Medicines (Interim)(7/8/2020 )  (Premium)
CDE Solicits Comments on the Draft Writing Guide and Common Format of Drug Production Processes, Quality Specifications and Package Inserts(7/6/2020 )  (Premium)
CDE Solicits Comments on the Draft Technical Guidelines for Marketing Registration of Non-prescription Chemical Drugs(7/6/2020 )  (Premium)
CDE Solicits Comments on the Draft Technical Guidelines for Clinical Testing of Immune Cell Therapy Products(7/6/2020 )  (Premium)
General Health
State Council Issues Guidance Opinions on Advancing BMI Fund Regulatory System Reform(7/10/2020 )  (Premium)
Swiss Re: Chinese Online Health Insurance Market to Grow 43% Annually Until 2025(7/8/2020 )  (Premium)
Legal/IPR News
NPC Solicits Comments on 2nd Draft of the Chinese Patent Law Amendment (with Summary of Pharma Patent Restoration & Linkage Provision)(7/6/2020 )  (Premium)
Product/R&D News
Evive Biotech Meets Endpoints in Global PIII Trial for Novel Chemotherapy-induced Neutropenia Drug(7/9/2020 )  (Premium)
Asieris Received Chinese Approval to Start a Global Phase III Trial of APL-1702 for Cervical Precancerous Lesions(7/9/2020 )  (Premium)
Chinese Alzheimer¡¯s Drug Rebuked Again by Top Local Neurologist(7/9/2020 )  (Premium)
GSK Files New Drug Application for IL-5 mAb Nucala (Mepolizumab) in China(7/8/2020 )  (Premium)
Sinovac Begins Phase III Trial of Its Coronavirus Vaccine in Brazil(7/8/2020 )  (Premium)
Ascentage and MSD in Clinical Trial Partnership to Evaluate APG-115 in Combo With KEYTRUDA in Advanced Solid Tumors(7/6/2020 )  (Premium)
People in the News
Recent Executive Moves(7/10/2020 )  (Premium)
© Wicon International Group¡¡Support by: www.heightow.com Home | Site map | Contact Us | Links